Ductal carcinoma in situ part I: Definition and diagnosis

Australian and New Zealand Journal of Surgery

Volumn 67, Issue 2-3, 1997, Pages 81-93

  Delaney, Geoff ^a   Ung, Owen ^a   Bilous, Michael ^a   Cahill, Stephen ^a   Greenberg, Merle ^a   Boyages, John ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

diagnosis; ductal carcinoma in situ; mammography; pathology

Indexed keywords

AUSTRALIA; BREAST CARCINOMA; BREAST DUCT; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CARCINOMA IN SITU; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAMMOGRAPHY; PATHOLOGY; REVIEW;

EID: 0030894903     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.1997.tb01909.x     Document Type: Review

References (149)

1. Delaney G, Ung O, Bilous M, Cahill S, Boyages J. Ductal carcinoma in situ Part II: treatment. Aust. N.Z. J. Surg. 1997 (in press).
2. Osteen RT. Paget's disease of the nipple. In: Harris JR (ed.). Breast Diseases, 2nd edn. Pennsylvania: J.B. Lippincott Co., 1991; Ch. 24.
3. Frykberg ER, Santiago F, Betsill WL, O'Brien PH. Lobular carcinoma in situ of the breast. Surg. Gynecol. Obstet. 1987; 164: 285-301.
4. Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA, Rosen PP. Breast carcinoma in situ. Arch. Surg. 1989; 124: 33-6.
5. Warren JC. Abnormal involution of the mammary gland with its treatment by operation. Am. J. Med. Sci. 1907; 134: 521-35.
6. Broders AC. Carcinoma in situ contracted with benign penetrating epithelium. JAMA 1932; 99: 1670-4.
7. Bloodgood JC. Comedo carcinoma (or comedo-adenoma) of the female breast. Am. J. Cancer. 1934; 22: 842-53.
8. Foote FW, Stewart FW. A histologic classification of carcinoma of the breast. Surgery 1946; 19: 74-99.
9. Rosner D, Bedwani RN, Vana PHJ, Baker HW, Murphy GP. Noninvasive breast carcinoma. Results of a national survey by the American College of Surgeons. Ann. Surg. 1980; 192: 139-47.
10. Anderson TJ, Alexander F, Chetty U et al. Comparative pathology of prevalent and incident cancers detected by breast screening, Lancet 1986; 1 (8480): 519-22.
11. Andersson I. Radiographic screening for breast carcinoma: Prognostic considerations on the basis of a short-term follow up. Acta Radiol. 1981; 22: 227-33.
12. Andersson I, Aspegren K, Janzon L et al. Mammographic screening and mortality from breast cancer: The Malmo mammographic screening trial. BMJ 1988; 297: 943-8.
13. Baker LH. Breast cancer detection demonstration project: Five-year summary report. CA Cancer J. Clin. 1982; 32: 194-225.
14. Ciatto S, Del Turco MR, Bonardi R et al. Non-palpable lesions of the breast detected by mammography - review of 1182 consecutive histologically confirmed cases. Eur. J. Cancer 1994; 30A: 40-4.
15. Dershaw DD, Abramson A, Kinne DW. Ductal carcinoma in situ: Mammographic findings and clinical implications. Radiology 1989; 170: 411-15.
16. Harrison RI, Glenn DC, Niesche FW et al. Surgical management of breast cancer - experience of the Central Sydney Area Health Service Breast X-ray Programme. 1988-1991. Med. J. Aust. 1994; 160: 617-20.
17. Papatestas AE, Hermann D, Hermann G, Tsevdos C, Lesnick G. Surgery for nonpalpable breast lesions. Arch. Surg. 1990; 125: 399-402.
18. Peer PGM, Holland R. Hendriks JHCL. Mravunac M, Verbeek ALM. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: Assessment of early indicators of screening effectiveness. J. Natl. Cancer Inst. 1994; 86: 436-41.
19. Schwartz GF, Feig SA, Patchefsky AS, Significance and staging of nonpalpable carcinomas of the breast. Surg. Gynecol. Obstet. 1988; 166: 6-10.
20. Symmonds RE, Roberts JW. Management of nonpalpable breast abnormalities. Ann. Surg. 1987; 205: 520-8.
21. Tabar L, Fagerberg CJ, Gad A et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985; 1: 829-32.
22. Tahar L, Fagerberg G, Chen H et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County trial. Cancer 1995; 75: 2507-17.
23. Tinnemans JGM, Wobbes T, Holland R. Hendriks JHCL, van der Sluis RF, De Boer HHM. Treatment and survival of female patients with nonpalpable breast carcinoma. Ann. Surg. 1989; 209: 249-53.
24. Heller KS, Rosen PP, Schottenfeld D. Ashikari R, Kinne DW. Male breast cancer. Ann. Surg. 1978; 188: 60-8.
25. Camus MG, Joshi MG, Mackarem G et al. Ductal carcinoma in situ of the male breast. Cancer 1994; 74: 1289-93.
26. National Program for the Early Detection of Breast Cancer-Monitoring and Evaluation Reference Group. Evaluation of Phase One: I July 1991-30 June 1994. Canberra: Commonwealth Department of Human Services and Health. 1994.
27. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum. Pathol. 1985; 16: 796-807.
28. Andersen J, Nielsen M, Christensen L. New aspects of the natural history of in situ and invasive carcinoma in the female breast. Results from autopsy investigations. Verh. Dtsch. Ges. Pathol. 1985; 69: 88-95.
29. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987; 60: 2751-60.
30. Bhathal PS, Brown RW, Lesueur GC. Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br. .J. Cancer 1985; 51: 271-8.
31. Frantz. VK, Pickren JW, Melcher GW, Auchincloss HJ. Incidence of chronic cystic disease in so called normal breasts: A study based on 225 post-mortem examinations. Cancer 1951; 4: 762-83.
32. Nielsen M, Jensen J, Andersen J, Precancerous and cancerous breast lesions during lifetime and at autopsy: A study of 83 women. Cancer 1984; 54: 612-15.
33. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U. Andersen JA. Breast cancer and atypia among young and middle-aged women: A study of 110 medicolegal autopsies. Br. J. Cancer 1987; 56: 814-19.
34. Kramer WM, Rush BF. Mammary duct proliferation in the elderly. A histopathologic study. Cancer 1973; 31: 130-7.
35. Rush BF, Kramer WM. Proliferative histologic changes and occult carcinoma in the breast of the aging female. Surg. Gynecol. Obstet. 1963; 117: 425-32.
36. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity. lymph node metastases and short-term treatment failures. Cancer 1982; 50: 1309-14.
37. Robbins GF, Berg JW. Bilateral primary breast cancers - a prospective clinicopathological study. Cancer 1964; 17: 1501-27.
38. Archer SG, Kemp BL, Gadd M, Shallenberger R, Ames FC, Singletary SE. Ductal carcinoma in situ of the breast: Comedo versus noncomedo subtype nonpredictive of recurrence or contralateral new breast primary. Breast Dis. 1994; 7: 353-60.
39. Arnesson L, Smeds S, Fagerberg G, Grontoft O. Follow-up of two treatment modalities for ductal cancer in situ of the breast. Br. J. Surg. 1989; 76: 672-5.
40. Ashikari R, Hajdu SI, Robbins GF. Intraductal carcinoma of the breast (1960-1969). Cancer 1971; 28: 1182-7.
41. Brown PW, Silverman J, Owens E, Tabor DC, Terz JJ, Lawrence WJ. Intraductal 'noninfiltrating' carcinoma of the breast. Arch. Surg. 1976; 111: 1063-7.
42. Webber BL, Heise H, Neifeld JP, Costa J. Risk of subsequent contralateral breast carcinoma in a population of patients with in-situ breast carcinoma. Cancer 1981; 47: 2928-32.
43. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 1982; 49: 751-8.
44. Betsill WL, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978; 239: 1863-7.
45. Rosen PP, Braun DW. Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer 1980; 46: 919-25.
46. Eusebi V, Foschini MP, Cook MG, Berrino F, Azzopardi JG. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin. Diagn. Pathol. 1989; 6: 165-73.
47. Eusebi V, Feudale E, Foschini MP et al. Long-term follow-up of in situ carcinoma of the breast. Semin. Diagn. Pathol. 1994; 11: 223-35.
48. Mourad WA, Setrakian S, Hales ML, Abdulla M, Trucco G. The argyrophilic nucleolar organizer regions in ductal carcinoma in situ of the breast. Cancer 1994; 74: 1739-45.
49. Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast: A comparison with histologic features. Cancer 1991; 68: 2602-7.
50. Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res. Treat. 1986; 7: 171-80.
51. Carpenter R, Gibbs N, Matthews J, Cooke T. Importance of cellular DNA content in pre-malignant breast disease and preinvasive carcinoma of the female breast. Br. J. Surg. 1987; 74: 905-6.
52. Cooke TG. Ductal carcinoma in situ: A new clinical problem. Br. J. Surg. 1989; 76: 660-2.
53. Zafrani B, Leroyer A, Fourquet A et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. Semin. Diagn. Pathol. 1994; 11: 208-14.
54. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin. Diagn. Pathol. 1994; 11: 199-207.
55. Nielsen KV, Blichert-Toft MD, Andersen JA. Chromosome analysis of in situ breast cancer. Acta Oncol. 1989; 28: 919-22.
56. Evans AJ, Pinder SE, Ellis IO et al. Correlation between the mammographic features of ductal carcinoma in situ (DClS) and C-erbB-2 oneogene expression. Clin. Radiol. 1994; 49: 559-62.
57. Somerville JE, Clarke LA. Biggart JD. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J. Clin. Pathol. 1992; 45: 16-20.
58. Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of C-erbB-2 protein in mammary ductal carcinoma in situ. Hum. Pathol. 1990; 21: 1164-7.
59. Poller DN, Silverstein MJ, Galea M et al. Ductal carcinoma in situ of the breast: A proposal for a new simplified histologic classification associated between cellular proliferation and c-erbB-2 protein expression. Mod. Pathol. 1994; 7: 257-62.
60. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R, Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69: 1174-81.
61. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 1988; 319: 1239-45.
62. Borg A, Linnell F, Idvall I et al. HER2/neu amplification and comedo-type breast carcinoma. Lancet 1989; 2: 1268-9.
63. Allred DC, Clark GM, Molina R et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 1992; 23: 974-9.
64. Barnes DM, Fischer CJ, Gillett CE, Millis RR, Lane DP. Implications of alterations in the structure of P53 tumour suppressor gene in human breast cancer. Br. J. Cancer 1992; 65: 975-6.
65. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. P53 protein expression in mammary ductal carcinoma in situ - relationship to immunohistochemical expression of estrogen and c-erbB-2 protein. Hum. Pathol. 1993; 24: 463-8.
66. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pthol. 1995; 26: 86-91.
67. Douglas-Jones AG, Schmid KW, Bier B et al. Metallothionein expression in duct carcinoma in situ of the breast. Hum. Pathol. 1995; 26: 217-22.
68. Locker AP, Horrocks C, Gilmour AS et al. Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br. J. Surg. 1990; 77: 564-7.
69. Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Hum. Pathol. 1993; 24: 16-23.
70. Cutuli B, Teissier E, Piat JM et al. Radical surgery and conservative treatment of ductal carcinoma in situ of the breast. Eur. J. Cancer 1992; 28: 649-54.
71. Rosen PP, Senie R, Schottenfeld D, Ashikari R. Non-invasive breast carcinoma: Frequency of unsuspected invasion and implications for treatment. Ann. Surg. 1979; 189: 377-82.
72. Schwartz GF, Feig SA, Rosenberg AL, Patchefsky AS, Schwartz AB. Staging and treatment of clinically occult breast cancer. Cancer 1984; 53: 1379-84.
73. Schwartz GF, Patchefsky AS, Finklestein SD et al. Non-palpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. Arch. Surg. 1989; 124: 29-32.
74. Silverstein MJ, Cohlan BF, Gierson ED et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur. J. Cancer. 1992; 28: 630-4.
75. Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast. 10 to 20 year follow-up. Arch. Surg. 1992; 127: 486-72.
76. Holland R, Hendriks JHCL. Verbeek ALM. Mravunac M, Schuurmans Stekhoven JH. Extent, distribution and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335: 519-22.
77. Frykberg ER, Bland KI. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 1994; 74: 350-61.
78. Rogers LW. Carcinoma in situ (CIS). In: Page DL, Anderson TJ (eds). Diagnostic Histopathology of the Breast, 1st edn. New York: Churchill Livingstone. 1987: Ch. 12.
79. Ringberg A, Palmer B, Linell F, Rychterova V, Ljunberg O. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ. Eur. J. Surg. Oncol. 1991; 17: 20-9.
80. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). Cancer 1995; 75: 1310-19.
81. Solin LJ, Yeh IT, Kurtz. J et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Cancer 1993; 71: 2532-42.
82. Kuske RR, Bean JM, Garcia DM et al. Breast conservation therapy for intraductal carcinoma of the breast. Int. J. Radiat. Oncol. Biol. Phys. 1993; 26: 391-6.
83. Schwartz, GF, Finkel GC, Garcia JC, Patchefsky AS. Sub-clinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 1992; 70: 2468-574.
84. Ringberg A, Idvall I, Anagnostaki L et al. Morphological and clinical characteristics in patients with ipsilateral recurrence after DCIS (Abstract). Eur. J. Cancer 1994; 30A (Suppl. 2): 574.
85. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast. Short term results of a prospective nationwide study. Am. J. Surg. Path. 1992; 16: 1183-96.
86. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg. Clin. North Am. 1990; 70: 853-71.
87. Silverstein MJ, Poller DN, Waisman JR et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-7.
88. Holland R, Peterse JL, Millis RR et al. Ductal carcinoma in situ: A proposal for a new classification. Semin. Diagn. Pathol. 1994; 11: 167-80.
89. Gallager HS, Martin JE. An orientation to the concept of minimal breast cancer. Cancer 1971; 28: 1505-7.
90. Ozzello L, Ultrastructure of intra-epithelial carcinomas of the breast. Cancer 1971; 28: 1508-15.
91. Barsky SH, Siegal GP, Jannotto F, Liotta LA. Loss of basement membrane components by invasive tumours but not by their benign counterparts. Lab. Invest. 1983; 49: 140-7.
92. Rosai J. Borderline epithelial lesions of the breast. Am. J. Surg. Path. 1991: 15: 209-21.
93. Schnitt SJ, Connolly JL, Tavassoli FA et al. Interobserver variability in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am. J. Surgery 1992; 16: 1133-43.
94. Sloane JP, Ellman R, Anderson TJ et al. Consistency of histopathologic reporting of breast lesions detected by screening: Findings of the UK National External Quality Assessment (EQA) scheme. Eur. J. Cancer 1994; 30A: 1414-19.
95. Sloane JP, Anderson TJ, Brown CL et al. Pathology reporting in breast cancer screening. J. Clin. Pathol. 1991; 44: 710-25.
96. Mus RDM, Boetes C. Barentsz JO et al. Combination of gadolinium enhanced subtracted dynamic turboFLASH and 3D MP-RAGE sequences in the diagnosis of breast cancer (Abstract). Radiology 1993; 189: 405.
97. Heywang-Kobrunner SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 1989; 171: 95-103.
98. Poon CS, Bronskill MJ, Henkelman RM, Boyd NF. Quantitative magnetic resonance imaging parameters and their relationship to mammographic pattern. J. Natl Cancer Inst. 1992; 84: 777-81.
99. Cross MJ, Harms SE, Cheek JH, Peters GN, Jones RC. New horizons in the diagnosis and treatment of breast cancer using magnetic resonance imaging. Am. J. Surgery 1993; 166: 749-55.
100. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190: 485-93.
101. Tinnemans JG, Wobbes T, Holland R et al. Mammographic and histopathologic correlation of nonpalpable lesions of the breast and the reliability of frozen section diagnosis. Surg. Gynecol. Obstet. 1987; 165: 523-9.
102. Gump FE, Jicha DL, Ozello L. Ductal carcinoma in situ (DCIS): A revised concept. Surgery 1987; 102: 790-5.
103. Reiff DB, Cooke J, Griffin M, Given-Wilson R. Ductal carcinoma in situ presenting as a stellate lesion on mammography. Clin. Radiol. 1994; 49: 396-9.
104. Stomper PC, Connolly JL, Meyer JE, Harris JR. Clinically occult ductal carcinoma in situ detected with mammography: Analysis of 100 cases with radiologie-pathologie correlation. Radiology 1989; 172: 235-41.
105. Rosen PP, Snyder RE, Robbins G. Specimen radiography for nonpalpable breast lesions found by mammography: Procedures and results. Cancer 1974; 34: 2028-33.
106. Bassett L, Mammographic analysis of calcifications. Radiol. Clin. North Am. 1992; 30: 93-105.
107. Monsees B. Evaluation of breast microcalcifications. Radiol. Clin. North Am. 1995; 33: 1109-21.
108. de Lafontan B, Daures JP, Salicru B et al. Isolated clustered microcalcifications: Diagnostic value of mammography - series of 400 cases with surgical verification. Radiology 1994; 190: 479-83.
109. American College of Radiology, Breast Imaging Reporting and Data Systems (BI-RADS). Reston, VA: American College of Radiology, 1993.
110. Holland R, Hendriks JHCL. Microcalcifications associated with ductal carcinoma in situ: Mammographic-pathologic correlation. Semin. Diagn. Pathol. 1994; 11: 181-92.
111. Sickles EA. Periodic mammographic follow up of probably benign lesions: Results in 3184 consecutive cases. Radiology 1991; 179: 463.
112. Varas X, Leborgne F, Leborgne JH. Non-palpable probably benign lesions: Role of follow up mammography. Radiology 1992; 184: 409.
113. Silverman JF, Masood S, Ducatman BS, Wang HH, Sneige N. Can FNA biopsy separate atypical hyperplasia carcinoma in situ and invasive carcinoma of the breast. Diagn. Cytopathol. 1993; 9: 713-28.
114. Orell SR, Sterrett GF. Walters MWI et al. Manual and Atlas of Fine Needle Aspiration Cytology, 2nd edn. Edinburgh: Churchill Livingstone, 1992.
115. Wang HH, Ducatman BS, Erick D. Comparative features of ductal carcinoma in situ and infiltrating ductal carcinoma of the breast on fine-needle aspiration biopsy. Am. J. Clin. Pathol. 1989; 92: 736-40.
116. Lindholm K. Cytology versus Histology in Carcinoma in situ of the Breast and the Role of Fine Needle Aspiration Cytology in the Treatment of Carcinoma in situ. Berlin: Springer-Verlager, 1995.
117. Venegas R, Rutgers JL, Cameron BL, Vargas H, Butler JA. Fine needle aspiration cytology of breast ductal carcinoma in situ. Acta Cytol. 1994; 38: 136-43.
118. Sneige N, White VA, Katz R, Trancoso P, Libshitz HI, Hortobagyi GN. Ductal carcinoma in situ of the breast: Fine-needle aspiration cytology of 12 cases. Diagn. Cytopathol. 1989; 5: 371-7.
119. Malamud YR, Ducatman BS, Wang HH. Comparative features of comedo and non-comedo ductal carcinoma in situ of the breast on fine needle aspiration biopsy. Diagn. Cytopathol. 1992; 8: 571-6.
120. Lilleng K, Hagmar BM, Farrants G. Low grade cribriform ductal carcinoma in situ of the breast. Fine needle aspiration cytology in three cases. Acta Cytol. 1992; 36: 48-54.
121. Theocharous C. Greenberg ML. Cytologic features of ductal carcinoma in situ. Diagn. Cytopathol. 1996 (in press).
122. Dowlatshahi K, Yaremko ML, Kluskens LF, Jokich PM. Non-palpable breast lesions: Findings or stereotactic needle core biopsy and fine needle aspiration cytology. Radiology 1991; 181: 745-50.
123. Parker SH, Lovin JD, Jobe WE, Burke BJ, Hopper KD, Yates WF. Non palpable breast lesion: Stereotactic automated large core biopsies. Radiology 1991; 180: 403-7.
124. Harter LP, Curtis JS, Ponto G, Craig PH. Malignant seeding of the needle track during stereotactic core needle breast biopsy. Radiology 1992; 185: 713-14.
125. Parker SH, Lovin JD, Jobe WE et al. Stereotactic breast biopsy with a biopsy gun. Radiology 1990; 176: 741-7.
126. Dronkers DJ. Stereotaxic core biopsy of breast lesions. Radiology 1992; 183: 631-4.
127. Elvecrog EL, Lechner MC, Nelson MT. Nonpalpable breast lesions: Correlation of Stereotaxic large-core needle biopsy and surgical biopsy results. Radiology 1993; 188: 453-5.
128. Parker SH, Burbank F. Jackman RJ et al. Percutaneous large core breast biopsy: A multi-institutional study. Radiology 1994; 193: 359-64.
129. Gisvold JJ, Goellner JR, Grant CS et al. Breast biopsy: A comparative study of stereotaxically guided core and excisional techniques. AJR 1994; 162: 815-20.
130. Reid SE, Scanlon EF, Bernstein JR, Paige ML, Matsumura J, Bailey L. An alternative approach to nonpalpable breast biopsies. J. Surg. Oncol. 1990; 44: 93-6.
131. Kopans DB, Swann CA. Preoperative imaging-guided needle placements and localization of clinically occult breast lesions. AJR 1989; 152: 1-9.
132. Horns JW, Arndt RD. Percutaneous spot localization of nonpalpable breast lesions. AJR 1976; 127: 253.
133. Czarnecki DJ. Feider HK, Splittgerber GF. Toluidine blue dye as a breast localization marker. AJR 1989; 153: 261-3.
134. Svane G. Stereotactic needle biopsy of non-palpable breast lesions. A clinic-radiologic follow-up. Acta Radiol. (Diagn.) 1983; 24: 385-90.
135. Dufrane P, Mazy G, Vanhaudenaerde C. Prebiopsy localization of nonpalpable breast cancer. JBR-BTR 1990; 73: 401-4.
136. Tubiana M, Holland R, Kopans DB et al. Commission of the European communities 'Europe against cancer' programme. European school of oncology advisory report. Management of non-palpable and small lesions found in mass breast screening. Eur. J. Cancer 1994: 30A: 538-47.
137. Homer MJ. Smith TJ. Safaii H. Prebiopsy needle localisation: Methods, problems and expected results. Radiol. Clin. North Am. 1992; 30: 139-53.
138. Jackson VP. Needle Localisation to Guide Excision Biopsy. Oak Brook. IL: Radiological Society of North America, 1995.
139. Recht A, van Dongen JA, Fentiman IS. Holland R, Peterse JL. Third meeting of the DCIS working party of the EORTC (Fondazione Cini. Isola S Giorgio, Venezia. 28 February 1994) - Conference report. Eur. J. Cancer 1994; 30A: 1895-1900.
140. Gluck BS, Dewshaw DD. Liberman L. Deutch BM. Microcalcifications on post-operative mammograms as an indication of adequacy of tumour excision. Radiology 1993; 188: 469-72.
141. Graham RA, Homer MJ, Sigler CJ et al. The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR 1994; 162: 33-6.
142. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens. A clinically-oriented approach. Am. J. Clin. Pathol. 1992; 98: 125-37.
143. Champ CS, Mason CH, Coghill SB, Robinson M. A perspex grid for localization of non-palpable mammographic lesions in breast biopsies. Histopathology 1989; 14: 311-15.
144. Armstrong JS, Davies JD. Laboratory handling of impalpable breast lesions: A review. J. Clin. Pathol. 1991; 44: 89-93.
145. Zafrani B, Contesso G, Eusebi V. Holland R. Millis RR, Peterse JL. Guidelines for the pathological management of mammographically detected breast lesions. Breast 1995; 4: 52-6.
146. Page DL, Lagios MD. Pathologic analysis of the national surgical adjuvant breast project (NSABP) B-17 trial. Unanswered questions remaining unanswered considering current concept of ductal carcinoma in situ. Cancer 1995; 75: 1219-22.
147. Going JJ, Anderson TJ, Crocker PR, Levison DA. Weddelite calcification in the breast: Eighteen cases with implications for breast cancer screening. Histopathology 1990; 16: 119-24.
148. Silverstein MJ, Gierson ED, Colburn WJ et al. Can intraductal breast carcinoma be excised completely by local excision? Cancer 1994; 73: 2985-9.
149. Bilous M, McCredie M, Porter L. Adequacy of histopathology reports for breast cancer in New South Wales. Pathology 1995; 27: 306-11.